Weekly Digest – December 2025 Weekly Digest – December 2025 01 December 2025: European Medicines Agency validates Type II Variation Application for PADCEV (Enfortumab vedotin) with KEYTRUDA (Pembrolizumab) for certain patients with muscle-invasive bladder cancer The EMA has validated Astellas’ […]
Weekly Digest – December 2025 Weekly Digest – December 2025 04 December 2025: Celltrion’s ADC anticancer drug ‘CT-P70’ receives Fast Track Designation from the US FDA Celltrion’s ADC candidate CT-P70 has received FDA Fast Track Designation for metastatic non-squamous NSCLC […]
Weekly Digest – December 2025 Weekly Digest – December 2025 01 December 2025: IDEAYA Biosciences announces IND clearance for IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC targeting multiple solid tumor types IDEAYA has received FDA IND clearance for IDE034, […]
